Wells Fargo Maintains Overweight on Halozyme Therapeutics, Lowers Price Target to $55
Wells Fargo analyst Mohit Bansal maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and lowers the price target from $65 to $55.
REE Automotive Q4 Cash And Equivalents $154M
As of December 31, 2022, the Company had $154 million of liquidity, comprised of cash, cash equivalents and short term investments, and no debt. The Company anticipates it has sufficient liquidity to achieve initial
Honest Co Q4 EPS $(0.14) Misses $(0.05) Estimate, Sales $81.86M Beat $80.37M Estimate
Honest Co (NASDAQ:HNST) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.05) by 180 percent. This is a 40 percent decrease over losses of $(0.10) per share from the same
Barclays Maintains Underweight on LivePerson, Lowers Price Target to $4
Barclays analyst Ryan Macwilliams maintains LivePerson (NASDAQ:LPSN) with a Underweight and lowers the price target from $11 to $4.
Goldman Sachs Initiates Coverage On Enhabit with Neutral Rating, Announces Price Target of $15
Goldman Sachs analyst Jamie Perse initiates coverage on Enhabit (NYSE:EHAB) with a Neutral rating and announces Price Target of $15.
VEON Q4 Sales $940.00M Down From $2.05B YoY
VEON (NASDAQ:VEON) reported $940.00 million in sales this quarter. This is a 54.19 percent decrease over sales of $2.05 billion the same period last year.